Encapsulated Papillary Thyroid Tumor with Delicate Nuclear Changes and a KRAS Mutation as a Possible Novel Subtype of Borderline Tumor
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Although papillary thyroid carcinoma (PTC)–type nuclear changes are the most reliable morphological feature in the diagnosis of PTC, the nuclear assessment used to identify these changes is highly subjective. Here, we report a noninvasive encapsulated thyroid tumor with a papillary growth pattern measuring 23 mm at its largest diameter with a nuclear score of 2 in a 26-year-old man. After undergoing left lobectomy, the patient was diagnosed with an encapsulated PTC. However, a second opinion consultation suggested an alternative diagnosis of follicular adenoma with papillary hyperplasia. When providing a third opinion, we identified a low MIB-1 labeling index and a heterozygous point mutation in the KRAS gene but not the BRAF gene. We speculated that this case is an example of a novel borderline tumor with a papillary structure. Introduction of the new terminology “noninvasive encapsulated papillary RAS-like thyroid tumor (NEPRAS)” without the word “cancer” might relieve the psychological burden of patients in a way similar to the phrase “noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).”
Abstract
Although papillary thyroid carcinoma (PTC)–type nuclear changes are the most reliable morphological feature in the diagnosis of PTC, the nuclear assessment used to identify these changes is highly subjective. Here, we report a noninvasive encapsulated thyroid tumor with a papillary growth pattern measuring 23 mm at its largest diameter with a nuclear score of 2 in a 26-year-old man. After undergoing left lobectomy, the patient was diagnosed with an encapsulated PTC. However, a second opinion consultation suggested an alternative diagnosis of follicular adenoma with papillary hyperplasia. When providing a third opinion, we identified a low MIB-1 labeling index and a heterozygous point mutation in the KRAS gene but not the BRAF gene. We speculated that this case is an example of a novel borderline tumor with a papillary structure. Introduction of the new terminology “noninvasive encapsulated papillary RAS-like thyroid tumor (NEPRAS)” without the word “cancer” might relieve the psychological burden of patients in a way similar to the phrase “noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).”
참고문헌 (20)
- Pappotti M, "WHO classification of tumours of endocrine organs", pp.73~74 (2017), International Agency for Research on Cance
- Chan JK, "WHO classification of tumours of endocrine organs", pp.76~77 (2017), International Agency for Research on Cancer
- Nikiforov YE, "Who classification of tumours of endocrine organs", pp.78~80 (2017), International Agency for Research on Cancer
- Nikiforov YE, "Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma : a paradigm shift to reduce overtreatment of indolent tumors", JAMA Oncol, 2, pp.1023~1029 (2016)
- Rosai J, "Renaming papillary microcarcinoma of the thyroid gland : the Porto proposal", Int J Surg Pathol, 11, pp.249~251 (2003)
- Hirokawa M, "Observer variation of encapsulated follicular lesions of the thyroid gland", Am J Surg Pathol, 26, pp.1508~1514 (2002)
- Chan J, "Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma", Am J Clin Pathol, 117, pp.16~18 (2002)
- Chan JK, "Endocrine malignancies that may mimic benign lesions", Semin Diagn Pathol, 12, pp.45~63 (1995)
- Williams ED, "Guest editorial : two proposals regarding the terminology of thyroid tumors", Int J Surg Pathol, 8, pp.181~183 (2000)
- Mitsutake N, "BRAF(V600E)mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima : a different oncogenic profile from Chernobyl", Sci Rep, 5, pp.16976~ (2015)
- Zhu Z, "Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma : an unusually high prevalence of ras mutations", Am J Clin Pathol, 120, pp.71~77 (2003)
- Cancer Genome Atlas Research Network, "Integrated genomic characterization of papillary thyroid carcinoma", Cell, 159, pp.676~690 (2014)
- Rivera M, "Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes(encapsulated vs infiltrative)reveals distinct BRAF and RAS mutation patterns", Mod Pathol, 23, pp.1191~1200 (2010)
- Radkay LA, "Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics", Cancer Cytopathol, 122, pp.873~882 (2014)
- Welch HG, "Overdiagnosis in cancer", J Natl Cancer Inst, 102, pp.605~613 (2010)
- Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer", Thyroid, 26, pp.1~133 (2016)
- Elisei R, "The BRAF(V600E)mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma : singleinstitution results from a large cohort study", J Clin Endocrinol Metab, 97, pp.4390~4398 (2012)
- Kakudo K, "The new 4th edition World Health Organization classification for thyroid tumors, Asian perspectives", Pathol Int, 68, pp.641~664 (2018)
- Kakudo K, "Classification of follicular cell tumors of the thyroid gland : analysis involving Japanese patients from one institute", Pathol Int, 59, pp.359~367 (2009)
- Adeniran AJ, "Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas", Am J Surg Pathol, 30, pp.216~222 (2006)